Business Wire Feed

Adaptyx Biosciences Presents First In-Human Continuous Multi-Day Free Cortisol Data From a Wearable Sensor at ADA, Providing a Time-resolved View of the Hormone Signal Driving Glucose Control, Cardiovascular Health, Stress Response, and Sleep

June 8th, 2026|

Late-breaking ADA data deliver two first in-human proof points: concordance between Adaptyx's wearable free-cortisol signal and paired venous blood measurements after a controlled oral hydrocortisone challenge, and continuous overnight monitoring of the body's own cortisol more...

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 8th, 2026|

CAMBRIDGE, Mass.--(BUSINESS WIRE)--$AMLX--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL. The first more...

OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

June 5th, 2026|

 Clinical data for TLC-6740 demonstrate additive metabolic benefits in combination with tirzepatide Novel preclinical findings for TLC-1180 demonstrate exercise-mimetic, insulin-sensitizing, and cognition-preserving effectsMENLO PARK, Calif.--(BUSINESS WIRE)--#ADA2026--OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.